Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.60 |
| ▸ | LTA4H | P09960 | 3/20 | 0.57 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.57 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | DRD4 | P21917 | 2/20 | 0.47 |
| ▸ | DRD2 | P14416 | 1/20 | 0.47 |
| ▸ | DRD3 | P35462 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | MAOB | P27338 | 2/20 | 0.46 |
| ▸ | ATM | Q13315 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL30624645 | 0.98 | TAAR1 (0.58) | TAAR1LTA4HPLA2G2AKDM4EALDH1A1 | |
| SCHEMBL20128987 | 0.89 | TSHR (0.50) | TAAR1LTA4HPLA2G2AKDM4EALDH1A1 | |
| SCHEMBL8432804 | 0.88 | DRD4 (0.50) | TAAR1LTA4HPLA2G2AKDM4EALDH1A1 | |
| SCHEMBL6714503 | 0.87 | TAAR1 (0.75) | TAAR1LTA4HPLA2G2AKDM4EALDH1A1 | |
| SCHEMBL2147268 | 0.86 | ATM (0.51) | TAAR1KDM4EALDH1A1DRD4DRD2 | |
| SCHEMBL6557649 | 0.85 | MAOB (0.57) | LTA4HKDM4EALDH1A1DRD4DRD2 | |
| SCHEMBL8918756 | 0.85 | ATM (0.50) | DRD4DRD2DRD3ATML3MBTL1 | |
| SCHEMBL18235025 | 0.82 | DRD4 (0.57) | LTA4HKDM4EALDH1A1DRD4DRD2 | |
| SCHEMBL17445905 | 0.82 | ATM (0.60) | LTA4HKDM4EALDH1A1DRD4DRD2 | |
| SCHEMBL7126896 | 0.81 | AGXT (0.46) | TAAR1LTA4HPLA2G2AKDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 98 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240390387-A1 | SULFONAMIDE OR SULFINAMIDE COMPOUND HAVING EFFECT OF INDUCING BRD4 PROTEIN DEGRADATION AND PHARMACEUTICAL USE THEREOF | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2024-11-28 | — | — | US | disclosed |
| US-12102641-B2 | Sulfonamide or sulfinamide compound having effect of inducing BRD4 protein degradation and pharmaceutical use thereof | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2024-10-01 | — | — | US | disclosed |
| CN-118401531-A | Benzimidazole compound and medical application thereof | 中国科学院上海药物研究所 | 2024-07-26 | — | — | CN | disclosed |
| US-11890288-B2 | Sulfonamide or sulfinamide compound having effect of inducing BRD4 protein degradation and pharmaceutical use thereof | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2024-02-06 | — | — | US | disclosed |
| CN-117025208-B | Composite light conversion powder, preparation method thereof and light conversion adhesive film | 江苏鹿山新材料有限公司 | 2023-12-08 | — | — | CN | disclosed |
| US-20230364105-A1 | SULFONAMIDE OR SULFINAMIDE COMPOUND HAVING EFFECT OF INDUCING BRD4 PROTEIN DEGRADATION AND PHARMACEUTICAL USE THEREOF | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2023-11-16 | — | — | US | disclosed |
| CN-117025208-A | Composite light conversion powder, preparation method thereof and light conversion adhesive film | 江苏鹿山新材料有限公司 | 2023-11-10 | — | — | CN | disclosed |
| WO-2023198901-A1 | NOVEL SUBSTITUTED 4-AMINO-4-OXO-BUT-2-ENYL DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND THERAPEUTIC USES THEREOF | SANOFI (FR) | 2023-10-19 | — | — | WO | disclosed |
| CN-116426227-B | Light conversion adhesive film containing composite light conversion agent, preparation method thereof and photovoltaic module | 江苏鹿山新材料有限公司 | 2023-08-11 | — | — | CN | disclosed |
| CN-116426227-A | Light conversion adhesive film containing composite light conversion agent, preparation method thereof and photovoltaic module | 江苏鹿山新材料有限公司 | 2023-07-14 | — | — | CN | disclosed |
| US-6201013-B1 | INOSINE MONOPHOSPHATE DEHYDROGENASE (IMPDH) INHIBITOR; SIDE EFFECT REDUCTION, NON-DRUG RESISTANT | AMERICAN HOME PRODUCTS CORPORATION | 2001-03-13 | — | — | US | disclosed |
| US-6197803-B1 | VIRICIDES; PREVENTION REPRODUCTION | AMERICAN HOME PRODUCTS CORPORATION | 2001-03-06 | — | — | US | disclosed |
| US-6166028-A | Diaminopuridine-containing thiourea inhibitors of herpes viruses | AMERICAN HOME PRODUCTS CORPORATION (US) | 2000-12-26 | — | — | US | disclosed |
| WO-2000034238-A1 | THIOUREA INHIBITORS OF HERPES VIRUSES | AMERICAN HOME PRODUCTS CORPORATION (US) | 2000-06-15 | — | — | WO | disclosed |
| WO-2000034260-A2 | ALPHA-METHYLBENZYL-CONTAINING THIOUREA INHIBITORS OF HERPES VIRUSES CONTAINING A PHENYLENEDIAMINE GROUP | AMERICAN HOME PRODUCTS CORPORATION (US) | 2000-06-15 | — | — | WO | disclosed |
| WO-2000034261-A2 | HETEROCYCLIC CARBOXAMIDE-CONTAINING THIOUREA INHIBITORS OF HERPES VIRUSES CONTAINING A SUBSTITUTED PHENYLENEDIAMINE GROUP | AMERICAN HOME PRODUCTS CORPORATION (US) | 2000-06-15 | — | — | WO | disclosed |
| WO-2000034237-A2 | ACETAMIDE AND SUBSTITUTED ACETAMIDE-CONTAINING THIOUREA INHIBITORS OF HERPES VIRUSES | AMERICAN HOME PRODUCTS CORPORATION (US) | 2000-06-15 | — | — | WO | disclosed |
| EP-0329016-B1 | Colour-photographic recording material | AGFA GEVAERT AG (DE) | 1994-03-23 | — | — | EP | disclosed |
| US-4119729-A | TREATMENT OF HYPERTENSION | MEAD JOHNSON & COMPANY (US) | 1978-10-10 | — | — | US | disclosed |
| US-4067904-A | ANTIARRHYTHMIA, HYPOTENSIVE | MEAD JOHNSON & COMPANY (US) | 1978-01-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11890288-B2 | Sulfonamide or sulfinamide compound having effect of inducing BRD4 protein degradation and pharmaceutical use thereof | BRD4, BRD1, BRD2 | TAAR1 3704/4885LTA4H 4473/4885PLA2G2A 4260/4885 |
| US-20230364105-A1 | SULFONAMIDE OR SULFINAMIDE COMPOUND HAVING EFFECT OF INDUCING BRD4 PROTEIN DEGRADATION AND PHARMACEUTICAL USE THEREOF | BRD4, BRD1, BRD2 | TAAR1 3704/4885LTA4H 4473/4885PLA2G2A 4260/4885 |
| US-12102641-B2 | Sulfonamide or sulfinamide compound having effect of inducing BRD4 protein degradation and pharmaceutical use thereof | BRD4, BRD1, BRD2 | TAAR1 3704/4885LTA4H 4473/4885PLA2G2A 4260/4885 |
| US-20240390387-A1 | SULFONAMIDE OR SULFINAMIDE COMPOUND HAVING EFFECT OF INDUCING BRD4 PROTEIN DEGRADATION AND PHARMACEUTICAL USE THEREOF | BRD4, BRD1, BRD2 | TAAR1 3704/4885LTA4H 4473/4885PLA2G2A 4260/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.